EICHOR
● Not Yet Recruiting
A Study of IOV-5001 in Adults With Advanced Solid Tumors
Condition: Advanced Solid Tumors · Non-Small Cell Lung Cancer · Triple Negative Breast Cancer (TNBC) · Sponsor: Iovance Biotherapeutics, Inc.
About this study
A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors
This description comes directly from the study's public registry record.
Talk to the study team
Iovance Biotherapeutics Study Team · 844-845-4682 · Clinical.Inquiries@iovance.com
Always discuss trial participation with your own doctor first.
Locations (0)
| Locations not yet listed on the registry record. |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07743723